Navigation Links
NanoBio to Announce Key Clinical and Preclinical Data in Nine Presentations at ICAAC/IDSA 2008
Date:10/21/2008

Findings confirm that NanoBio's nanoemulsion technology is effective when

used in therapeutic applications and vaccines

ANN ARBOR, Mich., Oct. 21 /PRNewswire/ -- NanoBio Corporation announced today that it will present compelling new data in nine presentations that detail key milestones in its clinical and preclinical development programs in onychomycosis, herpes labialis, cystic fibrosis and an intra-nasal influenza vaccine during the joint meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA) in Washington, DC, October 25-28.

The company's presentation schedule during the conference is detailed below. NanoBio will also exhibit at corporate booth #408.

Sunday, October 26, 2008

11:15 a.m. - 12:15 p.m. A Novel Nanoemulsion Adjuvant Enhancing the Immune Response to beta-propiolactone Inactivated Influenza Virus Using a Nasal Route in a Ferret Model, Poster #G-1194

Monday, October 27, 2008

11:15 a.m. - 12:15 p.m. Novel Nanoemulsion NB-001 Permeates Skin by the Follicular Route, Poster #A-1898

11:15 a.m. - 12:15 p.m. NB-002, a Novel Nanoemulsion with Anti-Dermatophyte Activity, Poster #M-2134

11:15 a.m. - 12:15 p.m. Mechanism of Skin Penetration and Distribution of a Novel Nanoemulsion, Poster #M-2135

12:15 p.m. - 1:15 p.m. Safety, Tolerability and Pharmacokinetics of NB-001 in a Phase 2 Dose-Ranging Trial in Subjects with Recurrent Herpes Labialis, Presentation #V-3539

12:15 p.m. - 1:15 p.m. NB-001, A Novel Nanoemulsion Active Against Acyclovir (ACV)- and Foscarnet (FOS)-Resistant Herpes Simplex Virus (HSV) 1 and 2, Poster #V-3538

Tuesday, October 28, 2008

9:00 a.m. - 9:15 a.m. Oral Presentation: Subject-Assessed Time to Healing in a Randomized, Double-Blind, Vehicle-Controlled Trial of a Novel Topical Antiviral Nanoemulsion (NB-001) for Recurrent Herpes Labialis

11:15 a.m. - 12:15 p.m. Novel Nanoemulsion Antimicrobials Tested Against Nine Gram-Positive Species, Poster #F1-3944

11:15 a.m. - 12:15 p.m. Antimicrobial Activity of Nanoemulsions Tested Against Seven Gram-Negative Species, Poster #F1-3945

About NanoBio:

NanoBio(R) Corp. is a privately held biopharmaceutical company focused on developing and commercializing anti-infective products and mucosal vaccines derived from its patented NanoStat(TM) technology platform. The company's lead clinical product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), acne, cystic fibrosis and mucosal vaccines for influenza and hepatitis B. Company headquarters and laboratory facilities are located in Ann Arbor, Mich.


'/>"/>
SOURCE NanoBio Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Daniel B. Dubin, M.D., Joins NanoBio Corp.s Board of Directors
2. FierceBiotech Names NanoBio Corporation as One of the Fierce 15 Biotech Companies of 2008
3. David M. Stout Joins NanoBio Corporations Board of Directors
4. Dr. Joyce Sutcliffe Joins the NanoBio Team as Vice President of Research
5. NanoBio Expands Drug Development Team for Its Anti-Infective Products
6. Cephalon and Eurand Announce Notification of Generic Filing for Cyclobenzaprine Hydrochloride Extended-Release Capsules
7. Advanced Life Sciences Announces Presentations at Fall Scientific and Investor Conferences and Third Quarter 2008 Earnings Conference Call
8. NxStage Announces Streamline(TM) Blood Tubing Set Supply Agreement with Renal Advantage Inc.
9. BioElectronics Announces Significant Progress in Canadian and International Distribution
10. Instrumentation Laboratory Announces Passion & Results Awards Program
11. CV Therapeutics Announces Presentations at American Heart Association Scientific Sessions 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Ky. and HOUSTON ... Inc. ("NX Prenatal") today announced the formation of ... together leading clinicians and industry veterans who enhance ... company as it accelerates development of its novel ... to provide medical, clinical and strategic guidance for ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... of product vigilance software to leading biopharmaceutical and medical device manufacturers and regulators, ... a fully 21 CFR Part 11-compliant email client designed to provide product vigilance ...
(Date:1/19/2017)... ... 18, 2017 , ... The American Medical Informatics Association (AMIA) ... Sharing Policy. Specifically, the nation’s leading informatics experts, said data sharing plans should ... AMIA recommended that NIH earmark funding for researchers to produce and execute data ...
(Date:1/19/2017)... NEW YORK , Jan. 18, 2017 /PRNewswire/ ... expected to reach USD 92.9 billion by 2025, ... Research, Inc. Pharmaceutical industry has been adaptive of ... functions as early as 2002. Among the services ... the forerunners. For instance, Johnson & Johnson was ...
Breaking Biology Technology:
(Date:12/16/2016)... 16, 2016 The global wearable medical device market, in ... 2021 from USD 5.31 billion in 2016, at a CAGR of ... ... technological advancements in medical devices, launch of a growing number of ... connectivity among healthcare providers, and increasing focus on physical fitness. ...
(Date:12/15/2016)... Mich. , Dec. 15, 2016  There is ... car doors or starting the engine. Continental will demonstrate ... Las Vegas . Through the combination ... Start and Entry) and biometric elements, the international technology ... of vehicle personalization and authentication. "The integration ...
(Date:12/7/2016)... to a new market research report "Emotion Detection and Recognition Market by Technology ... End User, And Region - Global Forecast to 2021", published by MarketsandMarkets, the ... USD 36.07 Billion by 2021, at a Compound Annual Growth Rate (CAGR) of ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):